Publications by authors named "Edward J Spangenthal"
Background: Immune checkpoint inhibitors (ICI) have emerged as a front-line therapy for a variety of solid tumors. With the widespread use of these agents, immune-associated toxicities are increasingly being recognized, including fatal myocarditis. There are limited data on the outcomes and prognostic utility of biomarkers associated with ICI-associated myocarditis.
View Article and Find Full Text PDFArticle Synopsis
- An 84-year-old man had a serious health issue where he was diagnosed with colon cancer after experiencing blood in his stool.
- He had a history of heart problems and needed special treatments to help his heart before getting surgery for the cancer.
- After surgery, he recovered well and is healthy with no signs of the cancer coming back for over a year!
Anthracyclines constitute the backbone of intensive adult acute myeloid leukemia (AML) therapy. Cardiotoxicity is one of its most serious adverse effects, and its incidence increases with cumulative dose. Dexrazoxane is a cardioprotective agent used in conjunction with anthracycline therapy.
View Article and Find Full Text PDFCancer therapeutics is undergoing a revolution with the advent of new drugs that can selectively target molecules responsible for carcinogenesis and tumor growth. The type and mechanism of these targeting drugs vary. Some are small molecules that specifically target a binding site on a receptor or signal transduction molecule.
View Article and Find Full Text PDF